BrainsWay stock rises after Optum expands Deep TMS coverage for adolescents, boosting reimbursement visibility.
BrainsWay Ltd. (BWAY) Analyst/Investor Day Transcript
BrainsWay Ltd. ( BWAY ) Q3 2025 Earnings Call November 11, 2025 8:30 AM EST Company Participants Hadar Levy - Chief Executive Officer Ido Marom - Chief Financial Officer Conference Call Participants Brian Ritchie - Lifesci Advisors, LLC Jeffrey Cohen - Ladenburg Thalmann & Co. Inc., Research Division Carl Byrnes - Northland Capital Markets, Research Division Raghuram Selvaraju - H.C.
| Health Care Technology Industry | Healthcare Sector | Hadar Levy CEO | NASDAQ (NMS) Exchange | 10501L106 CUSIP |
| IL Country | 120 Employees | - Last Dividend | 4 Mar 2026 Last Split | 6 Oct 1999 IPO Date |
BrainsWay Ltd. is a pioneering medical technology company focused on developing and providing noninvasive neurostimulation treatments for a variety of mental health disorders. Founded in 2003 and based in Jerusalem, Israel, the company has made significant strides in offering innovative healthcare solutions not only in the United States but also on an international scale. BrainsWay is dedicated to improving the lives of individuals suffering from mental health issues through its advanced Deep Transcranial Magnetic Stimulation (dTMS) platform technology. This commitment extends to a vast clientele including doctors, hospitals, and medical centers that specialize in psychiatry.
BrainsWay Ltd. offers a broad spectrum of treatments for mental health disorders through its flagship Deep Transcranial Magnetic Stimulation (dTMS) platform technology. Each application of this technology targets specific conditions, providing a noninvasive alternative to traditional treatments. The range of disorders addressed includes: